Rebellion21: Alteplase for Stroke of Unknown Time of Onset

In this 9 minute video from day 2 of Rebellion in EM 2021, I go over the evidence for advanced imaging use in acute ischemic stroke of unknown time of onset to help guide treatment with intravenous alteplase.

What They Did:

  • Systematic review and meta-analysis of individual patient data of trials
  • RCTs of IV tPA vs standard care or placebo in adults with stroke of unknown time of onset + perfusion-diffusion MRI, perfusion CT, or MRI with diffusion weighted imaging-fluid attenuated inversion recovery (DWI-MRI)

Primary Outcome: Favorable functional outcome (Score of 0 to 1 on the mRS) at 90d

Results:

  • 4 trials met eligibility criteria (843 patients could have meta-analysis performed)
    • WAKE-UP 503 patients using 0.9mg/kg alteplase
      • Terminated early due to cessation of funding
    • EXTEND 225 patients using 0.9mg/kg alteplase
      • Terminated early due to results of WAKE-UP
    • THAWS 131 patients using 0.6mg/kg alteplase
      • Terminated early due to results of WAKE-UP
    • ECASS-4 119 patients using 0.9mg/kg alteplase
      • Terminated early due to lack of recruitment
    • All 4 trials stopped early
  • Favorable Functional Outcome (mRS 0 to 1) at 90d (Primary Outcome):
    • Alteplase: 47%
    • Control: 39%
    • aOR 1.49; 95% CI 1.10 to 2.03; p = 0.011
    • NNT = 12
  • Death at 90d:
    • Alteplase: 6%
    • Control: 3%
    • aOR 2.06; 95% CI 1.03 to 4.09; p = 0.40
  • Symptomatic ICH:
    • Alteplase: 3%
    • Control: <1%
    • aOR 5.58; 1.22 to 25.50; p = 0.024

Limitations:

  • All 4 trials stopped early and only had modest sample sizes which limits the strength/precision of the findings and can overestimate benefit of the individual trials
  • Only one study used 0.6mg/kg of intravenous alteplase and therefore no definitive conclusions can be made about lower dosing vs higher dosing from this meta-analysis
  • The requirement of advanced imaging beyond non-contrast CT and vessel imaging might still be a potential limitation for implementation in some regions

Discussion:

  • The availability of perfusion imaging can affect all stroke care, where time is no longer brain. There will be plenty of patients who present <3 hours with no penumbra and no mismatch. This group may not require thrombolysis and perfusion imaging can help confirm that and spare them the potential harms
  • One thing to consider in this study is that despite having a lower number of deaths in the control group (mRS 6) compared to alteplase there were far more patients who were bedridden (mRS 5). This is a tough one to wrestle with from a patient care standpoint.  Do we save a life at the expense of being bedridden or do we spare the patient being bedridden at the expense of death?

Bottom Line: This meta-analysis provides level 1a evidence for the use of advanced brain imaging beyond non-contrast CT to help guide treatment with intravenous alteplase in patients with acute ischemic stroke with an unknown time of onset.  However, despite a consistently better functional outcome at 90d with alteplase compared to placebo or standard of care there was still an increased risk of symptomatic intracranial hemorrhage and a higher mortality which has also been consistent across all randomized clinical trials. 

Reference:

  1. Thomalla G et al. Intravenous Alteplase for Stroke with Unknown Time of Onset Guided by Advanced Imaging: Systematic Review and Meta-Analysis of Individual Patient Data. Lancet 2020. PMID: 33176180

Post Peer Reviewed By: Anand Swaminathan, MD (Twitter: @EMSwami)

Cite this article as: Salim Rezaie, "Rebellion21: Alteplase for Stroke of Unknown Time of Onset", REBEL EM blog, September 25, 2021. Available at: https://rebelem.com/rebellion21-alteplase-for-stroke-of-unknown-time-of-onset/.
The following two tabs change content below.

Salim Rezaie

Emergency Physician at Greater San Antonio Emergency Physicians (GSEP)
Creator & Founder of REBEL EM

Like this article?

Share on facebook
Share on Facebook
Share on twitter
Share on Twitter
Share on linkedin
Share on Linkdin
Share on email
Share via Email

Want to support rebelem?

Leave a Comment

Time limit is exhausted. Please reload CAPTCHA.

Sponsored

0